低剂量控释吗啡治疗特发性肺纤维化相关咳嗽:PACIFY COUGH随机交叉试验
PACIFY COUGH为英国三中心2期随机双盲安慰剂对照双向交叉试验,44例特发性肺纤维化伴咳嗽患者随机接受控释吗啡5 mg每日两次或安慰剂各14天。
要点
- 低剂量控释吗啡14天可显著降低特发性肺纤维化患者客观清醒期咳嗽频率。
- 吗啡组不良反应40%,主要为恶心14%和便秘21%,需监测。
- 研究为2期短期交叉试验,长期疗效与安全性尚待验证。
核心结论
- 在特发性肺纤维化相关咳嗽患者中,低剂量控释吗啡较安慰剂显著降低14天内的客观咳嗽计数。
- 吗啡有望成为姑息性治疗特发性肺纤维化咳嗽的有效选择,未来需开展更长程研究。
研究设计与样本
- PACIFY COUGH为2期、多中心、随机、双盲、安慰剂对照、双向交叉试验,在英国三个专科中心开展。
- 纳入40-90岁、5年内诊断为特发性肺纤维化、自报咳嗽持续>8周且咳嗽VAS≥30 mm的患者。
- 44例患者按1:1随机接受控释吗啡5 mg口服每日两次或安慰剂各14天,洗脱期7天。
- 主要终点为意向性治疗人群第14天客观清醒期咳嗽频率(次/小时)较基线的百分比变化。
主要发现
- 吗啡组43例中17例(40%)出现不良事件,安慰剂组42例中6例(14%)。
- 主要不良反应为恶心(43例中6例,14%)和便秘(43例中9例,21%)。
- 安慰剂组发生1例严重不良事件(死亡)。
关键数值与推荐
- 纳入标准:年龄40-90岁、特发性肺纤维化诊断5年内、自报咳嗽>8周、咳嗽VAS≥30 mm。
- 干预:控释吗啡5 mg口服每日两次,疗程14天,洗脱期7天。
- 主要终点:第14天客观清醒期咳嗽频率较基线百分比变化。
- 治疗依从性吗啡组98%、安慰剂组98%。
临床怎么用
- 对特发性肺纤维化合并顽固性咳嗽患者,可考虑短期低剂量控释吗啡作为姑息治疗选择。
- 用药期间应关注恶心、便秘等不良反应并做好对症处理。
局限性
- 为2期短期交叉试验,样本量44例,仅观察14天,长期疗效与安全性未评估。
- 研究在英国三个专科中心开展,外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease, with most patients reporting cough. Currently, there are no proven treatments. We examined the use of low dose controlled-release morphine compared with placebo as an antitussive therapy in individuals with idiopathic pulmonary fibrosis. METHODS: The PACIFY COUGH study is a phase 2, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial done in three specialist centres in the UK. Eligible patients aged 40-90 years had a diagnosis of idiopathic pulmonary fibrosis within 5 years, self-reported cough (lasting >8 weeks), and a cough visual analogue scale (VAS) score of 30 mm or higher. Patients were randomly assigned (1:1) to placebo twice daily or controlled-release morphine 5 mg orally twice daily for 14 days followed by crossover after a 7-day washout period. Patients were randomised sequentially to a sequence group defining the order in which morphine and placebo were to be given, according to a computer-generated schedule. Patients, investigators, study nurses, and pharmacy personnel were masked to treatment allocation. The primary endpoint was percentage change in objective awake cough frequency (coughs per h) from baseline as assessed by objective digital cough monitoring at day 14 of treatment in the intention-to-treat population, which included all randomised participants. Safety data were summarised for all patients who took at least one study drug and did not withdraw consent. This study was registered at ClinicalTrials.gov, NCT04429516, and has been completed. FINDINGS: Between Dec 17, 2020, and March 21, 2023, 47 participants were assessed for eligibility and 44 were enrolled and randomly allocated to treatment. Mean age was 71 (SD 7·4) years, and 31 (70%) of 44 participants were male and 13 (30%) were female. Lung function was moderately impaired; mean forced vital capacity (FVC) was 2·7 L (SD 0·76), mean predicted FVC was 82% (17·3), and mean predicted diffusion capacity of carbon monoxide was 48% (10·9). Of the 44 patients who were randomised, 43 completed morphine treatment and 41 completed placebo treatment. In the intention-to-treat analysis, morphine reduced objective awake cough frequency by 39·4% (95% CI -54·4 to -19·4; p=0·0005) compared with placebo. Mean daytime cough frequency reduced from 21·6 (SE 1·2) coughs per h at baseline to 12·8 (1·2) coughs per h with morphine, whereas cough rates did not change with placebo (21·5 [SE 1·2] coughs per h to 20·6 [1·2] coughs per h). Overall treatment adherence was 98% in the morphine group and 98% in the placebo group. Adverse events were observed in 17 (40%) of 43 participants in the morphine group and six (14%) of 42 patients in the placebo group. The main side-effects of morphine were nausea (six [14%] of 43 participants) and constipation (nine [21%] of 43). One serious adverse event (death) occurred in the placebo group. INTERPRETATION: In patients with cough related to idiopathic pulmonary fibrosis, low dose controlled-release morphine significantly reduced objective cough counts over 14 days compared with placebo. Morphine shows promise as an effective treatment to palliate cough in patients with idiopathic pulmonary fibrosis, and longer term studies should be the focus of future research. FUNDING: The Jon Moulton Charity Trust.
引用
- Wu Z, Spencer LG, Banya W, et al. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. Lancet Respir Med. 2024. PMID: 38237620. doi:10.1016/S2213-2600(23)00432-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。